GPT Healthcare Limited (GPTHEALTH.NS)
INR 181.0
(-0.12%)
INR 181.0
(-0.12%)
| Breakdown | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|
| Operating Cash Flow | 688 Million | 663.55 Million | 659.92 Million | 439.28 Million | 414.65 Million |
| Net Income | 680.43 Million | 559.69 Million | 540.79 Million | 288.83 Million | 109.56 Million |
| Depreciation & Amortization | 179.81 Million | 149.12 Million | 135.9 Million | 124.72 Million | 108.34 Million |
| Deferred income taxes | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - |
| Change in working capital | -61.69 Million | 20.29 Million | 54.57 Million | -90.92 Million | -62.45 Million |
| Other non-cash items | 23.32 Million | 38.79 Million | 62.88 Million | 80.77 Million | 259.2 Million |
| Investing Cash Flow | -252.05 Million | 51.53 Million | -53.39 Million | -173.85 Million | -543.09 Million |
| Investments in PPE | -193.75 Million | -99.46 Million | -105.72 Million | -69.82 Million | -470.47 Million |
| Acquisitions | - | - | - | - | - |
| Investment purchases | -360.72 Million | -100.03 Million | -342.04 Million | -110 Thousand | - |
| Sales/Maturities of investments | 141.5 Million | 54.41 Million | 243.93 Million | - | - |
| Other Investing Activities | -58.3 Million | 10 Thousand | 19.57 Million | -104.03 Million | -72.62 Million |
| Financing Cash Flow | -485 Million | -731.77 Million | -571.61 Million | -221.13 Million | 119.11 Million |
| Debt repayment | -526.22 Million | -311.32 Million | -274.79 Million | -60.45 Million | -280.23 Million |
| Dividends payments | -239.71 Million | -319.61 Million | -172.59 Million | -134.38 Million | -10 Thousand |
| Common Stock Repurchased | - | - | - | - | - |
| Common Stock Issuance | 400 Million | - | - | - | - |
| Other Financing Activities | 325.35 Million | -92.08 Million | -95.93 Million | -191.44 Million | -161.11 Million |
| Accounts receivables | -54.27 Million | -77.35 Million | 36.42 Million | -6.11 Million | -76 Million |
| Accounts payables | - | - | - | - | - |
| Inventory | 7.65 Million | -16.36 Million | -8.59 Million | -1.25 Million | -15.65 Million |
| Other working capital | -60.25 Million | 61.74 Million | -6.15 Million | -25.96 Million | 29.2 Million |
| Cash at beginning of period | 65.99 Million | 82.68 Million | 47.76 Million | 3.46 Million | 12.79 Million |
| Cash at end of period | 16.93 Million | 65.99 Million | 82.68 Million | 47.76 Million | 3.46 Million |
| Capital Expenditure | -193.75 Million | -99.46 Million | -105.72 Million | -69.82 Million | -470.47 Million |
| Effect of forex changes on cash | - | - | - | - | - |
| Net cash flow / Change in cash | -49.06 Million | -16.68 Million | 34.92 Million | 44.3 Million | -9.33 Million |
| Free Cash Flow | 494.25 Million | 564.09 Million | 554.2 Million | 369.46 Million | -55.82 Million |
| Breakdown | 2024 Q1 | 2023 FY | 2023 Q4 | 2023 Q3 | 2023 Q2 | 2023 Q1 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | 99.64 Million | 680.43 Million | 128.16 Million | 114.7 Million | 135.06 Million | 99.79 Million |
| Depreciation & Amortization | - | 179.81 Million | - | - | 43.1 Million | 42.82 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | - | -61.69 Million | - | - | -92.98 Million | -33.48 Million |
| Other non-cash items | -99.64 Million | 23.32 Million | -128.16 Million | -114.7 Million | 110.73 Million | 34.94 Million |
| Investing Cash Flow | - | -252.05 Million | - | - | -85.25 Million | 21.82 Million |
| Investments in PPE | - | -193.75 Million | - | - | -63.36 Million | -51.36 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | -360.72 Million | - | - | - | - |
| Sales/Maturities of investments | - | 141.5 Million | - | - | - | - |
| Other Investing Activities | - | -58.3 Million | - | - | -21.89 Million | 73.18 Million |
| Financing Cash Flow | - | -485 Million | - | - | -124.73 Million | -175.11 Million |
| Debt repayment | - | -526.22 Million | - | - | -65.05 Million | -60.72 Million |
| Dividends payments | - | -239.71 Million | - | - | -79.91 Million | -79.9 Million |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | 400 Million | - | - | - | - |
| Other Financing Activities | - | 325.35 Million | - | - | 20.23 Million | -34.49 Million |
| Accounts receivables | - | -54.27 Million | - | - | -38.31 Million | -43.83 Million |
| Accounts payables | - | - | - | - | - | - |
| Inventory | - | 7.65 Million | - | - | -4.54 Million | -2.12 Million |
| Other working capital | - | -60.25 Million | - | - | -50.13 Million | 12.47 Million |
| Cash at beginning of period | - | 65.99 Million | - | 42.7 Million | 56.77 Million | 65.99 Million |
| Cash at end of period | - | 16.93 Million | - | 42.7 Million | 42.7 Million | 56.77 Million |
| Capital Expenditure | - | -193.75 Million | - | - | -63.36 Million | -51.36 Million |
| Effect of forex changes on cash | - | - | - | - | - | - |
| Net cash flow / Change in cash | - | -49.06 Million | - | - | -14.07 Million | -9.22 Million |
| Free Cash Flow | - | 494.25 Million | - | - | 132.55 Million | 92.71 Million |
AGRO3
GWO-PN
VAYK
UNITECH
NERV
GBIO